Search details
1.
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Endocr Pract
; 28(10): 923-1049, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35963508
2.
CONCENTRATED INSULINS: CLINICAL UPDATE OF THERAPEUTIC OPTIONS.
Endocr Pract
; 26(Suppl 3): 1-12, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32339033
3.
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.
Endocr Pract
; 26(10): 1196-1224, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-33471721
4.
FATTY KIDNEY DISEASE: A NEW RENAL AND ENDOCRINE CLINICAL ENTITY? DESCRIBING THE ROLE OF THE KIDNEY IN OBESITY, METABOLIC SYNDROME, AND TYPE 2 DIABETES.
Endocr Pract
; 25(8): 854-858, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31013163
5.
AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES.
Endocr Pract
; 23(11): 1345-1349, 2017 Nov.
Article
in English
| MEDLINE | ID: mdl-29190135
6.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Endocr Pract
; 22(6): 753-62, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27082665
7.
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Endocr Pract
; 21(8): 917-26, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-26121451
8.
Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring.
Endocr Pract
; 21(5): 522-33, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25962091
9.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY.
Endocr Pract
; 21(12): 1403-14, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26642101
10.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Endocr Pract
; 26(1): 107-139, 2020 01.
Article
in English
| MEDLINE | ID: mdl-32022600
11.
American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action.
Endocr Pract
; 20(9): 956-76, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25253226
12.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Endocr Pract
; 25(1): 69-100, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30742570
13.
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
N Engl J Med
; 362(16): 1463-76, 2010 Apr 22.
Article
in English
| MEDLINE | ID: mdl-20228402
14.
Effect of valsartan on the incidence of diabetes and cardiovascular events.
N Engl J Med
; 362(16): 1477-90, 2010 Apr 22.
Article
in English
| MEDLINE | ID: mdl-20228403
15.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Endocr Pract
; 24(1): 91-120, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29368965
16.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Endocr Pract
; 23(2): 207-238, 2017 02.
Article
in English
| MEDLINE | ID: mdl-28095040
17.
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
J Diabetes Complications
; 36(2): 108101, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34922811
18.
REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES.
Endocr Pract
; 22(11): 1343-1346, 2016 11.
Article
in English
| MEDLINE | ID: mdl-27540881
19.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.
Endocr Pract
; 22(1): 84-113, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26731084
20.
COMBINING CREATININE-BASED eGFR WITH CYSTATIN C-BASED EGFR TO BETTER ASSESS RENAL FUNCTION IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE 3A: IMPLICATIONS FOR DRUG SELECTION AND DOSAGE IN TYPE 2 DIABETES.
Endocr Pract
; 21(11): 1301-2, 2015 Nov.
Article
in English
| MEDLINE | ID: mdl-26509856